Literature DB >> 21715005

Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia.

Sang Hyuk Park1, Hyun-Sook Chi, Sook-Kyung Min, Borae G Park, Seongsoo Jang, Chan-Jeoung Park.   

Abstract

This study sought to define the prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia (CBF AML) patients. A total of 116 patients diagnosed as CBF AML in Asan Medical Center from January 1999 to May 2010 were enrolled in this study. We applied melting curve analyses and direct sequencing methods to confirm c-KIT mutations in exon 17 (mutKIT17) and exon 8 (mutKIT8). Of the total 116 patients, mutKIT17 were found in 36 (31%) and mutKIT8 were found in 7 (6%). In patients with t(8;21), prognosis was significantly poorer in those with mutKIT17 compared to those without the mutation. This difference was limited to adults. In patients with inv(16), there was no prognostic impact of c-KIT mutations. Therefore, an analysis of mutKIT17 in adult CBF AML patients with t(8;21) is recommended as a means to predict prognosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715005     DOI: 10.1016/j.leukres.2011.06.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  37 in total

Review 1.  Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

Authors:  Xi Quan; Jianchuan Deng
Journal:  Mol Clin Oncol       Date:  2020-05-25

2.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia.

Authors:  Wen DU; Yanjie Hu; Cong Lu; Juan Li; Wei Liu; Yanli He; Ping Wang; Chen Cheng; Y U Hu; Shiang Huang; Junxia Yao; Jin'e Zheng
Journal:  Mol Clin Oncol       Date:  2015-04-24

Review 4.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 5.  Progress in acute myeloid leukemia.

Authors:  Tapan M Kadia; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-09-19

Review 6.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

7.  KIT proto-oncogene exon 8 deletions at codon 419 are highly frequent in acute myeloid leukaemia with inv(16) in Indian population.

Authors:  Syed Rizwan Hussain; Hena Naqvi; Farzana Mahdi; Cherry Bansal; Sunil G Babu
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

8.  Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation.

Authors:  Jae-Ho Yoon; Hee-Je Kim; Seung-Hwan Shin; Seung-Ah Yahng; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

9.  Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.

Authors:  Gautam Borthakur; Jorge E Cortes; Elihu E Estey; Elias Jabbour; Stefan Faderl; Susan O'Brien; Guillermo Garcia-Manero; Tapan Mahendra Kadia; Xuemei Wang; Keyur Patel; Rajyalakshmi Luthra; Charles Koller; Mark Brandt; Farhad Ravandi; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2014-07-21       Impact factor: 10.047

10.  High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML.

Authors:  Yue Zhao; Qi Liu; Pankaj Acharya; Kristy R Stengel; Quanhu Sheng; Xiaofan Zhou; Hojoong Kwak; Melissa A Fischer; James E Bradner; Stephen A Strickland; Sanjay R Mohan; Michael R Savona; Bryan J Venters; Ming-Ming Zhou; John T Lis; Scott W Hiebert
Journal:  Cell Rep       Date:  2016-08-04       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.